HeartFlow, a medical technology company, is revolutionizing the diagnosis and treatment of heart disease with its non-invasive HeartFlow FFRct Analysis. This technology uses deep learning to create a personalized 3D model of the heart, allowing clinicians to better evaluate the impact of a blockage on blood flow and determine the best treatment. However, the company faced a significant challenge. Cardiovascular disease, the world’s leading cause of death, claims more than 17 million lives each year. The most common type, coronary artery disease (CAD), reduces blood flow to the heart, causing chest pain, heart attack, and death. Clinicians need to know if and where there is a blockage, and how it is affecting blood flow. This information is crucial in choosing the best treatment pathway for the patient, such as medical management, stenting or bypass surgery. However, the diagnostic coronary angiogram often used to detect CAD is invasive, expensive, and potentially risky. More than half of patients who undergo the test have no significant blockages, and the procedure can be associated with serious complications.